Skip to main content

Advertisement

SpringerLink
Log in

Role of Radiation Therapy in the Treatment of Hodgkin Lymphoma

  • B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (D Persky, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Radiation therapy has historically been the pillar of curative treatment for Hodgkin lymphoma (HL). With improved efficacy of systemic therapy and the ever-increasing recognition of treatment-related morbidity in long-term survivors, the role of radiotherapy has evolved significantly. Modern combined modality therapy (CMT) with multi-agent chemotherapy followed by involved site radiation therapy (ISRT) to initially involved sites of disease remains the gold standard for the majority of patients with HL. Reduction of long-term treatment-related toxicity has become the major driver in clinical trial design for early-stage HL while improved disease-specific survival remains the goal in patients with more advanced and unfavorable disease. This review will address the data supporting the use of radiotherapy in HL as well as specific methods for reducing late toxicity from radiotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Noordijk EM, et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL). J Clin Oncol. 2005;23(16_suppl):6505–6505.

  2. Engert A, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363(7):640–52.

    Article  CAS  PubMed  Google Scholar 

  3. •• Radford J, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372(17):1598–607. UK NCI RAPID response-adapted trial. Addition of RT to ABVD × 4 for PET negative patients resulted in 6% improvement in 3-year EFS.

    Article  CAS  PubMed  Google Scholar 

  4. •• Andre ́ M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol. 2017. doi:10.1200/JCO.2016.68.6394. Patients with early-stage favorable and unfavorable HL with negative interim PET following ABVD randomized to ± XRT. Radiotherapy randomization stopped early by DSMC when significant improvement in PFS demonstrated with CMT.

  5. Meyer RM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med. 2012;366(5):399–408.

    Article  CAS  PubMed  Google Scholar 

  6. Hay AE, et al. An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. Ann Oncol. 2013;24(12):3065–9.

    Article  CAS  PubMed  Google Scholar 

  7. Herbst C, et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin’s lymphoma: a systematic review. Haematologica. 2010;95(3):494–500.

    Article  CAS  PubMed  Google Scholar 

  8. Koshy M, et al. Declining use of radiotherapy in stage I and II Hodgkin’s disease and its effect on survival and secondary malignancies. Int J Radiat Oncol Biol Phys. 2012;82(2):619–25.

    Article  PubMed  Google Scholar 

  9. Parikh RR, et al. Early-stage classic Hodgkin lymphoma: the utilization of radiation therapy and its impact on overall survival. Int J Radiat Oncol Biol Phys. 2015;93(3):684–93.

    Article  PubMed  Google Scholar 

  10. Aleman BM, et al. Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med. 2003;348(24):2396–406.

    Article  PubMed  Google Scholar 

  11. •• Johnson PW, et al. Consolidation radiotherapy in patients with advanced Hodgkin’s lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J Clin Oncol. 2010;28(20):3352–9. Study evaluating ABVD vs alternate multi-drug chemo in patients with bulky stage II, or stage III or IV. RT was recommended for patients who presented with bulky adenopathy or who failed to achieve a complete response by CT. XRT utilization associated with significant improvement in 5-year PFS and OS.

    Article  PubMed  Google Scholar 

  12. Eich HT, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin study group HD11 trial. J Clin Oncol. 2010;28(27):4199–206.

    Article  PubMed  Google Scholar 

  13. Engert A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791–9.

    Article  CAS  PubMed  Google Scholar 

  14. Krasin MJ, et al. Patterns of treatment failure in pediatric and young adult patients with Hodgkin’s disease: local disease control with combined-modality therapy. J Clin Oncol. 2005;23(33):8406–13.

    Article  PubMed  Google Scholar 

  15. Picardi M, et al. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin’s lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma. 2007;48(9):1721–7.

    Article  PubMed  Google Scholar 

  16. Johnson P, Federico M, Fossa A, Barrington S, Kirkwood A, Roberts T, et al., Response rates and toxicity of response-adapted therapy in advanced Hodgkin lymphoma: Initial results from the international RATHL study. Haematologica. 2013;98(s2).

  17. Dhakal S, et al. Patterns and timing of initial relapse in patients subsequently undergoing transplantation for Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2009;75(1):188–92.

    Article  PubMed  Google Scholar 

  18. Dharmarajan KV, et al. Patterns of relapse from a phase 3 study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the children’s oncology group. Int J Radiat Oncol Biol Phys. 2015;92(1):60–6.

    Article  PubMed  Google Scholar 

  19. •• Specht L, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89(4):854–62. International consensus guidelines for target delineation with involved site radiotherapy (ISRT)

    Article  PubMed  Google Scholar 

  20. Girinsky T, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol. 2006;79(3):270–7.

    Article  PubMed  Google Scholar 

  21. Maraldo MV, et al. Involved node radiation therapy: an effective alternative in early-stage hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2013;85(4):1057–65.

    Article  PubMed  Google Scholar 

  22. Paumier A, et al. Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2011;80(1):199–205.

    Article  PubMed  Google Scholar 

  23. Kriz J, et al. Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study group. Int J Radiat Oncol Biol Phys. 2015;92(1):46–53.

    Article  PubMed  Google Scholar 

  24. Weber DC, et al. Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients. Int J Radiat Oncol Biol Phys. 2011;81(2):490–7.

    Article  PubMed  Google Scholar 

  25. Hodgson DC, et al. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer. 2007;110(11):2576–86.

    Article  PubMed  Google Scholar 

  26. Schaapveld M, et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med. 2015;373(26):2499–511.

    Article  CAS  PubMed  Google Scholar 

  27. Giri S, et al. Incidence of breast cancer among female survivors of Hodgkin lymphoma: a US-population-based trend analysis from 1973 to 2011. Blood. 2015;126(15):1861–3.

    Article  CAS  PubMed  Google Scholar 

  28. • Conway JL, et al. Secondary breast cancer risk by radiation volume in women with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2017;97(1):35–41. Large population database study demonstrating no increased risk of breast cancer development with small-volume mediastinal radiotherapy.

    Article  PubMed  Google Scholar 

  29. Ibrahim EM, et al. Risk of second breast cancer in female Hodgkin’s lymphoma survivors: a meta-analysis. BMC Cancer. 2012;12:197.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Castellino SM, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. 2011;117(6):1806–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Eriksson F, et al. Long-term cardiac mortality following radiation therapy for Hodgkin’s disease: analysis with the relative seriality model. Radiother Oncol. 2000;55(2):153–62.

    Article  CAS  PubMed  Google Scholar 

  32. Ng AK, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger. J Clin Oncol. 2002;20(8):2101–8.

    Article  PubMed  Google Scholar 

  33. van Nimwegen FA, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol. 2016;34(3):235–43.

    Article  PubMed  Google Scholar 

  34. Swerdlow AJ, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007;99(3):206–14.

    Article  PubMed  Google Scholar 

  35. Paumier A, et al. Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2012;82(4):1522–7.

    Article  PubMed  Google Scholar 

  36. Aznar MC, et al. Minimizing late effects for patients with mediastinal Hodgkin lymphoma: deep inspiration breath-hold, IMRT, or both? Int J Radiat Oncol Biol Phys. 2015;92(1):169–74.

    Article  PubMed  Google Scholar 

  37. Cella L, et al. Hodgkin’s lymphoma emerging radiation treatment techniques: trade-offs between late radio-induced toxicities and secondary malignant neoplasms. Radiat Oncol. 2013;8:22.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Inskip PD, et al. Radiation-related new primary solid cancers in the Childhood Cancer Survivor Study: comparative radiation dose response and modification of treatment effects. Int J Radiat Oncol Biol Phys. 2016;94(4):800–7.

    Article  PubMed  Google Scholar 

  39. Voong KR, et al. Dosimetric advantages of a “butterfly” technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin’s lymphoma. Radiat Oncol. 2014;9:94.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Andolino DL, et al. Dosimetric comparison of involved-field three-dimensional conformal photon radiotherapy and breast-sparing proton therapy for the treatment of Hodgkin’s lymphoma in female pediatric patients. Int J Radiat Oncol Biol Phys. 2011;81(4):e667–71.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University of Arizona, 1501 N Campbell Ave., Tucson, AZ, 85724, USA

    Victor J. Gonzalez

Authors
  1. Victor J. Gonzalez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Victor J. Gonzalez.

Ethics declarations

Conflict of Interest

Victor J Gonzalez declares no potential conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on B-cell NHL, T-cell NHL, and Hodgkin Lymphoma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gonzalez, V.J. Role of Radiation Therapy in the Treatment of Hodgkin Lymphoma. Curr Hematol Malig Rep 12, 244–250 (2017). https://doi.org/10.1007/s11899-017-0385-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-017-0385-y

Keywords

Search

Navigation